SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Clinical trials for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Nasal spray could slow brain damage in progressive MS
Disease control Recruiting nowThis study tests a nasal spray called foralumab in people with non-active secondary progressive multiple sclerosis (SPMS), a form of MS that worsens over time. The goal is to see if the drug can reduce brain inflammation and slow disability without serious side effects. About 54 …
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Tiziana Life Sciences LTD • Aim: Disease control
Last updated May 26, 2026 04:58 UTC
-
Could a cancer drug tame multiple sclerosis? new trial launches
Disease control Recruiting nowThis study is testing whether a drug called ixazomib, which is already used for a type of cancer, is safe for people with multiple sclerosis (MS). The drug targets certain immune cells that may drive MS. About 72 adults with relapsing-remitting or progressive MS will take either …
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
Could a stem cell transplant stop MS in its tracks?
Disease control Recruiting nowThis study compares a stem cell transplant (AHSCT) with the best standard treatments for people whose relapsing multiple sclerosis (MS) is not controlled by usual therapies. About 156 adults aged 18 to 55 will be randomly assigned to one of the two approaches and followed for 6 y…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for slowing progressive MS: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial tests whether the drug orelabrutinib can slow disability progression in people with non-active secondary progressive multiple sclerosis (SPMS). About 990 adults aged 18-60 will be randomly assigned to receive either orelabrutinib or a placebo for 12 to 60 month…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated May 20, 2026 11:58 UTC